The key COVID-19 findings in endocrinology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
29cited sources
13available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY41%higher relative risk
COVID-19 survivors had higher new-onset diabetes risk
In a systematic review and meta-analysis, COVID-19 survivors had a 41% higher relative risk of new-onset diabetes than non-infected individuals.
This pooled post-acute result is relative, not absolute. Follow-up, population details, and underlying study designs are not available in this summary, so it should not be read as causal.
See the evidence
41% higher relative risk, calculated from RR 1.41. This is not an absolute percentage-point difference.
41% increased risk of new-onset diabetes in COVID-19 survivors compared to non-infected individuals
RR 1.41 95% CI: 1.38-1.44
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Elevated HbA1c levels indicating impaired glycemic control
SMD 1.44 95% CI: 0.36-2.52
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Among adults without preexisting diabetes, HbA1c was 5.39% before infection and 5.40% at 12 months after COVID-19, with no established difference.
This is a longitudinal within-group comparison. The same study reported metabolic-syndrome incidence and increased estimated cardiovascular risk, so HbA1c does not represent every metabolic outcome.
See the evidence
HbA1c from pre-infection to 12 months after COVID-19 among adults without preexisting diabetes
5.39% vs 5.40%; P = .435
Daher, Joviane et al.. Glucose metabolism across COVID-19 and long COVID: a longitudinal study.. Journal of the Endocrine Society. 2026.
Glucose variability was linked to short-term hospital mortality
A meta-analysis found that high glucose variability was associated with short-term all-cause mortality among hospitalized COVID-19 patients.
The reference glucose-variability group is not available in this summary, so the pooled relative-risk estimate is not featured. The association does not establish that variability caused death.
See the evidence
High glucose variability associated with increased short-term all-cause mortality in hospitalized COVID-19 patients
RR 2.10 95% CI: 1.69-2.59
Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.
Association in younger patients (mean age <62 years)
RR 1.78
Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.
Stronger association in older patients (mean age ≥62 years)
RR 2.79
Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.
Stable HbA1c coexisted with other metabolic findings
Among adults without preexisting diabetes, HbA1c was 5.39% before infection and 5.40% at 12 months, with no established change.
The study also reported new-onset metabolic syndrome in 18%-20% across long-COVID categories, with persistence more frequent at greater severity, and estimated 10-year cardiovascular risk rising from 6.7% to 7.3%. The latter is not an observed event rate.
Study details & original results
Daher, Joviane et al.. Glucose metabolism across COVID-19 and long COVID: a longitudinal study.. Journal of the Endocrine Society. 2026.
HbA1c from pre-infection to 12 months after COVID-19 among adults without preexisting diabetes
5.39% vs 5.40%; P = .435
New-onset metabolic syndrome incidence across long COVID categories; persistent metabolic syndrome was more frequent with more severe long COVID
18%-20%
Change in estimated 10-year ASCVD risk after COVID-19
Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.
Muller JA, Gross R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149-165.
Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol. 2020;8(8):659-660.
Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany. JAMA. 2022;328(8):790-792.
Barrett CE, Koyama AK, Alvarez P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years. MMWR Morb Mortal Wkly Rep. 2022;71(2):59-65.
Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2021;106(2):e926-e935.
Montefusco L, Ben Nasr M, D'Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-785.
Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870-874.
Wroblewski I, et al. Type 1 diabetes risk in children following COVID-19 infection - Norwegian cohort study. 2024.
Original source link unavailable
[26]
Qian, Jiahui et al.. New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.. International journal of epidemiology. 2026.
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Wang, Zixuan et al.. Glycemic variability and the short-term mortality of hospitalized patients with COVID-19: a meta-analysis.. Frontiers in endocrinology. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.